Morgan Stanley Point Biopharma Global Inc. Transaction History

Morgan Stanley

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	SELL	$6.67 - $9.71 $503,358 - $732,774	-75,466 Reduced 37.05%	128,244 $855,000
Q2 2023 Aug 14, 2023	BUY	$6.86 - $10.86 $343,644 - $544,020	50,094 Added 32.61%	203,710 $1.85 Million
Q1 2023 May 15, 2023	BUY	$6.78 - $8.1 $731,873 - $874,362	107,946 Added 236.36%	153,616 $1.12 Million
Q4 2022 Feb 14, 2023	BUY	$5.72 - $9.78 $147,272 - $251,805	25,747 Added 129.23%	45,670 $332,000
Q3 2022 Nov 14, 2022	SELL	$7.24 - $10.31 $410,898 - $585,133	-56,754 Reduced 74.02%	19,923 $155,000
Q2 2022 Oct 27, 2022	BUY	$5.6 - $9.5 $346,875 - $588,449	61,942 Added 420.37%	76,677 $521,000
Q2 2022 Aug 15, 2022	BUY	$5.6 - $9.5 $346,875 - $588,449	61,942 Added 420.37%	76,677 $521,000
Q1 2022 Oct 27, 2022	SELL	$5.46 - $8.13 $338,203 - $503,588	-61,942 Reduced 80.78%	14,735 $117,000
Q1 2022 May 13, 2022	BUY	$5.46 - $8.13 $48,211 - $71,787	8,830 Added 149.53%	14,735 $117,000
Q4 2021 Feb 14, 2022	BUY	$4.83 - $9.75 $11,688 - $23,595	2,420 Added 69.44%	5,905 $33,000
Q3 2021 Nov 15, 2021	BUY	$7.42 - $11.26 $25,858 - $39,241	3,485 New	3,485 $27,000

20K

Ticker PNT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 104,025,000
Description
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate canc...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.